1. Home
  2. SUPN vs LIVN Comparison

SUPN vs LIVN Comparison

Compare SUPN & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • LIVN
  • Stock Information
  • Founded
  • SUPN 2005
  • LIVN 1987
  • Country
  • SUPN United States
  • LIVN United Kingdom
  • Employees
  • SUPN N/A
  • LIVN N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • SUPN Health Care
  • LIVN Health Care
  • Exchange
  • SUPN Nasdaq
  • LIVN Nasdaq
  • Market Cap
  • SUPN 1.8B
  • LIVN 2.1B
  • IPO Year
  • SUPN 2012
  • LIVN 1993
  • Fundamental
  • Price
  • SUPN $32.46
  • LIVN $47.09
  • Analyst Decision
  • SUPN Hold
  • LIVN Strong Buy
  • Analyst Count
  • SUPN 2
  • LIVN 7
  • Target Price
  • SUPN $36.00
  • LIVN $59.29
  • AVG Volume (30 Days)
  • SUPN 747.3K
  • LIVN 552.1K
  • Earning Date
  • SUPN 08-05-2025
  • LIVN 08-06-2025
  • Dividend Yield
  • SUPN N/A
  • LIVN N/A
  • EPS Growth
  • SUPN N/A
  • LIVN N/A
  • EPS
  • SUPN 1.11
  • LIVN N/A
  • Revenue
  • SUPN $667,997,000.00
  • LIVN $1,275,380,000.00
  • Revenue This Year
  • SUPN N/A
  • LIVN $8.10
  • Revenue Next Year
  • SUPN $12.02
  • LIVN $5.76
  • P/E Ratio
  • SUPN $29.24
  • LIVN N/A
  • Revenue Growth
  • SUPN 11.82
  • LIVN 7.62
  • 52 Week Low
  • SUPN $25.94
  • LIVN $32.48
  • 52 Week High
  • SUPN $40.28
  • LIVN $57.35
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 53.20
  • LIVN 61.98
  • Support Level
  • SUPN $31.35
  • LIVN $45.20
  • Resistance Level
  • SUPN $32.55
  • LIVN $47.17
  • Average True Range (ATR)
  • SUPN 0.91
  • LIVN 1.21
  • MACD
  • SUPN 0.04
  • LIVN -0.05
  • Stochastic Oscillator
  • SUPN 60.93
  • LIVN 93.98

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About LIVN LivaNova PLC

UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Share on Social Networks: